Financial Results for Year ending 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Drugs Limited reported strong revenue and profit growth for FY26. Standalone net sales jumped 105% to Rs. 7,585 lakhs from Rs. 3,693 lakhs in FY25, while consolidated net sales rose 74% to Rs. 7,874 lakhs. Standalone PAT more than tripled to Rs. 104 lakhs from Rs. 30 lakhs (251% growth), and consolidated PAT grew 214% to Rs. 106 lakhs. EPS improved to Rs. 0.93 standalone and Rs. 0.95 consolidated. However, the company raised Rs. 317.50 lakhs via equity share issuance and had additional warrant allotments during the year. The auditors issued unmodified opinions but raised emphasis of matters regarding Rs. 4.14 crore in trade receivables outstanding for over 2 years with no provision for doubtful debts, and unconfirmed balances for receivables, payables and advances.
The company shows impressive top-line and bottom-line growth, but the significant negative operating cash flow (standalone: Rs. -737 lakhs vs +Rs. 316 lakhs prior year) and large unexplained trade receivables growth raise concerns about cash conversion quality and potential revenue recognition issues. Shareholders should monitor receivables collection and cash flow sustainability closely.